Your institution may have access to this item. Find your institution then sign in to continue.
Title
Keytruda Now Approved for Neoadjuvant and Adjuvant Treatment of Resectable NSCLC.
Abstract
The article focuses on the Food and Drug Administration (FDA) recent approval of a new indication for pembrolizumab, a PD-1 inhibitor, for the neoadjuvant and adjuvant treatment of resectable cell lung cancer in combination with platinum-containing chemotherapy and single-agent pembrolizumab, respectively. Pembrolizumab showed improved overall survival and event-free survival rates compared to placebo, with common adverse events including nausea, fatigue, and decreased white blood cell count.